Is Novo Nordisk the Cisco of the GLP‑1 Era?

The chart tells a sobering story: Novo Nordisk's trajectory mirrors Cisco's dot-com bubble, just 20+ years later. Both rode transformative waves (internet infrastructure vs. obesity drugs), saw explosive growth, then faced reality.

Novo Nordisk's mistakes are quantifiable: aggressive headcount expansion, ballooning R&D expenses, failure to dominate the US market, intensifying competition from Eli Lilly, Trump's politics eroding margins.

The new CEO inherits a strategy crisis requiring genuine business innovation, not superficial AI-driven layoffs.

This isn't just Novo Nordisk's challenge. The Danish stock market faces broader pressures, with OMX Copenhagen down almost -27% YoY as global investors reassess Danish market valuation.

Can Novo Nordisk avoid Cisco's 20+ years recovery?

Will GLP-1 hype follow the same boom-bust pattern?

History doesn't repeat, but it often rhymes.